comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-29 21:14:11 - browse：5

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： BIO selects John Crowley as new CEO

WSS

Mayo Clinic plans $5B tech

Disappointing trial forces Pfizer to pivot on obesity medicine plans

The EPA's new lead rule: How one expert crunched the numbers

CDC director unscathed in first congressional testimony

What don’t we know about an Alzheimer’s drug side effect?

As biotech industry slumps, bioscience job market is upside down

leisure time

comprehensive

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

FDA approves first new drug developed for postpartum depression

Moonlake's readout produced a cash windfall. Risks remain

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Hollywood unions extend contract negotiations for actors

Senate panel passes drug pricing bills, but drops one PBM reform

Heart attack and stroke risk calculators need revising

The thinking behind the controversial eating disorder chatbot Tessa

hotspot

Cigna, Humana reportedly in talks to merge

Takeda, Janssen join wearable maker to measure scratching

Mom launches Girl Scout troop for LGBTQ youth in Texas

Pediatric cancer treatments threatened by a new FDA policy

A public health expert passes on football's full body collisions for youths

J&J to emphasize cancer drugs, stop much of its vaccine research

hotspot

Wikipedia

hotspot

explore